Protalix BioTherapeutics Inc’s recently made public that its Director Schwartz Aharon acquired Company’s shares for reported $0.21 million on Jun 10 ’25. In the deal valued at $1.60 per share,129,000 shares were bought. As a result of this transaction, Schwartz Aharon now holds 303,000 shares worth roughly $0.72 million.
H.C. Wainwright reiterated its Protalix BioTherapeutics Inc [PLX] rating to a Buy in a research note published on June 08, 2020; the price target was $11. A number of analysts have revised their coverage, including Rodman & Renshaw’s analysts, who remained covering the stock and in mid April has reiterated a ‘”a Buy”‘ rating for it. Rodman & Renshaw began covering PLX with “Buy” recommendation on April 04, 2016. Jefferies revised its rating on April 23, 2015. It rated PLX as “a Buy” which previously was an “a Hold”.
Price Performance Review of PLX
On Friday, Protalix BioTherapeutics Inc [AMEX:PLX] saw its stock fall -7.81% to $2.36. Over the last five days, the stock has lost -2.88%. Protalix BioTherapeutics Inc shares have risen nearly 131.37% since the year began. Nevertheless, the stocks have risen 25.53% over the past one year.
How much short interest is there in Protalix BioTherapeutics Inc?
A steep rise in short interest was recorded in Protalix BioTherapeutics Inc stocks on 2025-09-30, growing by 0.56 million shares to a total of 4.15 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 3.6 million shares. There was a rise of 13.4%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 12, 2014 when R. F. Lafferty resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $5.
